The absence of CD4+ T cell count recovery despite receipt of virologically suppressive highly active antiretroviral therapy: clinical risk, immunological gaps, and therapeutic options.
暂无分享,去创建一个
Giulia Marchetti | C. Tincati | G. Marchetti | A. Monforte | Lidia Gazzola | Camilla Tincati | Giusi Maria Bellistrì | Antonella d'Arminio Monforte | L. Gazzola | G. M. Bellistrì
[1] V. Calvez,et al. Restoration of the immune system with anti-retroviral therapy. , 1999, Immunology letters.
[2] R. Grant,et al. Increased production of IL-7 accompanies HIV-1–mediated T-cell depletion: implications for T-cell homeostasis , 2001, Nature Medicine.
[3] S. Sakaguchi. Naturally arising Foxp3-expressing CD25+CD4+ regulatory T cells in immunological tolerance to self and non-self , 2005, Nature Immunology.
[4] Hildegund C J Ertl,et al. Cyclosporin A provides no sustained immunologic benefit to persons with chronic HIV-1 infection starting suppressive antiretroviral therapy: results of a randomized, controlled trial of the AIDS Clinical Trials Group A5138. , 2006, The Journal of infectious diseases.
[5] M. Miller,et al. Impact of hepatitis C virus on immune restoration in HIV-infected patients who start highly active antiretroviral therapy: a meta-analysis. , 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[6] Richard D Moore,et al. Risk of Non-AIDS-Related Mortality May Exceed Risk of AIDS-Related Mortality Among Individuals Enrolling Into Care With CD4+ Counts Greater Than 200 Cells/mm3 , 2007, Journal of acquired immune deficiency syndromes.
[7] C. Chougnet,et al. Regulatory T cells (Treg) and HIV/AIDS: summary of the September 7-8, 2006 workshop. , 2007, AIDS research and human retroviruses.
[8] G. Luzi,et al. Altered clonogenic capability and stromal cell function characterize bone marrow of HIV-infected subjects with low CD4+ T cell counts despite viral suppression during HAART. , 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[9] M. Kazatchkine,et al. Discrepant responses to triple combination antiretroviral therapy in advanced HIV disease , 1998, AIDS.
[10] J. Metcalf,et al. In vivo expansion of CD4+CD45RO–CD25+ T cells expressing foxP3 in IL-2-treated HIV-infected patients , 2005 .
[11] R. Haubrich,et al. Cellular restoration in HIV infected persons treated with abacavir and a protease inhibitor: age inversely predicts naive CD4 cell count increase , 2000, AIDS.
[12] P. Sullivan,et al. Effect of hepatitis C infection on progression of HIV disease and early response to initial antiretroviral therapy , 2006, AIDS.
[13] G. Satten,et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. , 1998, The New England journal of medicine.
[14] C. Tincati,et al. Untangling the immunological implications of nadir on CD4+ cell recovery during suppressive highly active antiretroviral therapy. , 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[15] Rachael A. Hughes,et al. Long-term trends in CD4 count in patients starting HAART: UK-CHIC study , 2007 .
[16] Adriano Lazzarin,et al. Treatment of primary HIV-1 infection with cyclosporin A coupled with highly active antiretroviral therapy. , 2002, The Journal of clinical investigation.
[17] B. Yip,et al. Adherence to Antiretroviral Therapy and Cd4 T-Cell Count Responses among HIV-Infected Injection Drug Users , 2004, Antiviral therapy.
[18] D. Follmann,et al. Induction and maintenance therapy with intermittent interleukin-2 in HIV-1 infection. , 2004, Blood.
[19] T. Chun,et al. Relationship between the size of the human immunodeficiency virus type 1 (HIV-1) reservoir in peripheral blood CD4+ T cells and CD4+:CD8+ T cell ratios in aviremic HIV-1-infected individuals receiving long-term highly active antiretroviral therapy. , 2002, The Journal of infectious diseases.
[20] Alison A Motsinger,et al. Immunogenetics of CD4 lymphocyte count recovery during antiretroviral therapy: An AIDS Clinical Trials Group study. , 2006, The Journal of infectious diseases.
[21] S. Moreno,et al. Long-term outcomes among antiretroviral-naive human immunodeficiency virus-infected patients with small increases in CD4+ cell counts after successful virologic suppression. , 2002, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[22] P. Harrigan,et al. The Impact of Adherence on CD4 Cell Count Responses Among HIV-Infected Patients , 2004, Journal of acquired immune deficiency syndromes.
[23] J. J. Henning,et al. Guidelines for the Use of Antiretroviral Agents in HIV-Infected Adults and Adolescents, January 28, 2000 , 1998, HIV clinical trials.
[24] J. Rakela,et al. Hepatitis C virus in lymphoid cells of patients coinfected with human immunodeficiency virus type 1: evidence of active replication in monocytes/macrophages and lymphocytes. , 2000, The Journal of infectious diseases.
[25] J. Metcalf,et al. In vivo expansion of CD4CD45RO-CD25 T cells expressing foxP3 in IL-2-treated HIV-infected patients. , 2005, The Journal of clinical investigation.
[26] D. Douek,et al. HIV disease: fallout from a mucosal catastrophe? , 2006, Nature Immunology.
[27] M. Betts,et al. A Pilot Study of the Use of Mycophenolate Mofetil as a Component of Therapy for Multidrug‐Resistant HIV‐1 Infection , 2001, Journal of acquired immune deficiency syndromes.
[28] R. Chung,et al. IMMUNE RECOVERY IS ASSOCIATED WITH PERSISTENT RISE IN HEPATITIS C VIRUS RNA, INFREQUENT LIVER TEST FLARES, AND IS NOT IMPAIRED BY HEPATITIS C VIRUS IN CO-INFECTED SUBJECTS , 2002, AIDS.
[29] A. Flahault,et al. Mechanisms involved in the low-level regeneration of CD4+ cells in HIV-1-infected patients receiving highly active antiretroviral therapy who have prolonged undetectable plasma viral loads. , 2005, The Journal of infectious diseases.
[30] A. Aiuti,et al. Improvement of interleukin 2 production, clonogenic capability and restoration of stromal cell function in human immunodeficiency virus‐type‐1 patients after highly active antiretroviral therapy , 2002, British journal of haematology.
[31] B. Gazzard,et al. Interleukin-2-associated viral breakthroughs induce HIV-1-specific CD4 T cell responses in patients on fully suppressive highly active antiretroviral therapy. , 2003, AIDS.
[32] R. Hershow,et al. Discordant CD4 T lymphocyte responses to antiretroviral therapy for HIV infection are associated with ex-vivo rates of apoptosis. , 2001, AIDS.
[33] C. Tincati,et al. Microbial translocation is associated with sustained failure in CD4+ T-cell reconstitution in HIV-infected patients on long-term highly active antiretroviral therapy , 2008, AIDS.
[34] H. Ullum,et al. Low-level viremia and proviral DNA impede immune reconstitution in HIV-1-infected patients receiving highly active antiretroviral therapy. , 2005, The Journal of infectious diseases.
[35] T. Fry,et al. The Many Faces of IL-7: From Lymphopoiesis to Peripheral T Cell Maintenance , 2005, The Journal of Immunology.
[36] M. Leal,et al. Patients' characteristics and clinical implications of suboptimal CD4 T-cell gains after 1 year of successful antiretroviral therapy. , 2008, Current HIV research.
[37] A. Westfall,et al. Clinical Outcome of HIV-Infected Antiretroviral-Naive Patients With Discordant Immunologic and Virologic Responses to Highly Active Antiretroviral Therapy , 2008, Journal of acquired immune deficiency syndromes.
[38] John L. Johnson,et al. A study of the safety, immunology, virology, and microbiology of adjunctive etanercept in HIV-1-associated tuberculosis , 2004, AIDS.
[39] P. Kissinger,et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. , 1998, The New England journal of medicine.
[40] J. Rakela,et al. The presence of active hepatitis C virus replication in lymphoid tissue in patients coinfected with human immunodeficiency virus type 1. , 1998, The Journal of infectious diseases.
[41] D. Farge,et al. First-line use of enfuvirtide-containing HAART regimen with dramatic clinical and immunological improvement in three cases. , 2006, AIDS.
[42] E. Nicastri,et al. Clinical outcome after 4 years follow‐up of HIV‐seropositive subjects with incomplete virologic or immunologic response to HAART , 2005, Journal of medical virology.
[43] T. Kenakin,et al. The CCR5 Receptor-Based Mechanism of Action of 873140, a Potent Allosteric Noncompetitive HIV Entry Inhibitor , 2005, Molecular Pharmacology.
[44] Lynne Peeples,et al. Class-sparing regimens for initial treatment of HIV-1 infection. , 2008, The New England journal of medicine.
[45] A. Phillips,et al. Short-term risk of AIDS according to current CD4 cell count and viral load in antiretroviral drug-naive individuals and those treated in the monotherapy era , 2003, AIDS.
[46] C. Apetrei,et al. Mucosal immune dysfunction in AIDS pathogenesis. , 2008, AIDS reviews.
[47] Mario Clerici,et al. Productive Infection Maintains a Dynamic Steady State of Residual Viremia in Human Immunodeficiency Virus Type 1-Infected Persons Treated with Suppressive Antiretroviral Therapy for Five Years , 2003, Journal of Virology.
[48] Michael S Saag,et al. Treatment for adult HIV infection: 2006 recommendations of the International AIDS Society--USA panel. , 2006, Topics in HIV medicine : a publication of the International AIDS Society, USA.
[49] M. Lederman,et al. Poor CD4 T cell restoration after suppression of HIV-1 replication may reflect lower thymic function , 2001, AIDS.
[50] C. Vigouroux,et al. Contribution of Mitochondrial Dysfunction and Oxidative Stress to Cellular Premature Senescence Induced by Antiretroviral Thymidine Analogues , 2008, Antiviral therapy.
[51] M. Leal,et al. T-cell repopulation and thymic volume in HIV-1-infected adult patients after highly active antiretroviral therapy. , 2002, Blood.
[52] O. Kirk,et al. Factors associated with a reduced CD4 lymphocyte count response to HAART despite full viral suppression in the EuroSIDA study , 2003, HIV medicine.
[53] M. Kazatchkine,et al. Clinical Outcome of Patients with HIV-1 Infection according to Immunologic and Virologic Response after 6 Months of Highly Active Antiretroviral Therapy , 2000, Annals of Internal Medicine.
[54] A. d’Arminio Monforte,et al. CD4 cell counts at the third month of HAART may predict clinical failure. , 1999, AIDS.
[55] M. Lederman,et al. A potential role for interleukin-7 in T-cell homeostasis. , 2001, Blood.
[56] A. Moses,et al. The influence of human immunodeficiency virus-1 on hematopoiesis. , 1998, Blood.
[57] G. Marchetti,et al. Partial immune reconstitution following highly active antiretroviral therapy: can adjuvant interleukin-2 fill the gap? , 2005, The Journal of antimicrobial chemotherapy.
[58] M. John,et al. HLA-Bw4 homozygosity is associated with an impaired CD4 T cell recovery after initiation of antiretroviral therapy. , 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[59] E. Wherry,et al. Therapeutic use of IL-2 to enhance antiviral T-cell responses in vivo , 2003, Nature Medicine.
[60] A. Esposito,et al. T-cell homeostasis alteration in HIV-1 infected subjects with low CD4 T-cell count despite undetectable virus load during HAART , 2006, AIDS.
[61] J. Flamm,et al. Severe CD4+ T-Cell Depletion in Gut Lymphoid Tissue during Primary Human Immunodeficiency Virus Type 1 Infection and Substantial Delay in Restoration following Highly Active Antiretroviral Therapy , 2003, Journal of Virology.
[62] A. Mocroft,et al. Influence of age on CD4 cell recovery in human immunodeficiency virus-infected patients receiving highly active antiretroviral therapy: evidence from the EuroSIDA study. , 2001, The Journal of infectious diseases.
[63] M. Kozal,et al. A comparison of three highly active antiretroviral treatment strategies consisting of non-nucleoside reverse transcriptase inhibitors, protease inhibitors, or both in the presence of nucleoside reverse transcriptase inhibitors as initial therapy (CPCRA 058 FIRST Study): a long-term randomised trial , 2006, The Lancet.
[64] M. Moroni,et al. Low-dose prolonged intermittent interleukin-2 adjuvant therapy: results of a randomized trial among human immunodeficiency virus-positive patients with advanced immune impairment. , 2002, The Journal of infectious diseases.
[65] S. Rosenberg,et al. IL-7 Administration to Humans Leads to Expansion of CD8+ and CD4+ Cells but a Relative Decrease of CD4+ T-Regulatory Cells , 2006, Journal of immunotherapy.
[66] R. Badolato. Immunological nonresponse to highly active antiretroviral therapy in HIV-infected subjects: is the bone marrow impairment causing CD4 lymphopenia? , 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[67] Richard D Moore,et al. CD4+ cell count 6 years after commencement of highly active antiretroviral therapy in persons with sustained virologic suppression. , 2007, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[68] A. d’Arminio Monforte,et al. Response to combination antiretroviral therapy: variation by age , 2008, AIDS.
[69] Martin S. Hirsch,et al. Treatment for adult HIV infection. , 2004 .
[70] P. Massip,et al. Analysis of CCR5, CCR2, CX3CR1, and SDF1 polymorphisms in HIV-positive treated patients: impact on response to HAART and on peripheral T lymphocyte counts. , 2006, AIDS research and human retroviruses.
[71] A. De Maria. Discordant responses to HAART in HIV-1 patients: the need to focus on intervention , 2007, Expert review of anti-infective therapy.
[72] M. Plana,et al. Residual low-level viral replication could explain discrepancies between viral load and CD4+ cell response in human immunodeficiency virus-infected patients receiving antiretroviral therapy. , 2000, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[73] S. Hammer,et al. Antiretroviral therapy for HIV infection in 1998: updated recommendations of the International AIDS Society-USA Panel. , 1997, JAMA.
[74] M. Clerici,et al. Tumor necrosis factor-alpha increased production during thalidomide treatment in patients with tuberculosis and human immunodeficiency virus coinfection. , 2000, The Journal of infectious diseases.
[75] Jonathan AC Sterne,et al. Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies , 2002, The Lancet.
[76] E. Sandström,et al. Clinical and immunological benefits from highly active antiretroviral therapy in spite of limited viral load reduction in HIV type 1 infection. , 2001, AIDS research and human retroviruses.
[77] Michael D. George,et al. Viral Suppression and Immune Restoration in the Gastrointestinal Mucosa of Human Immunodeficiency Virus Type 1-Infected Patients Initiating Therapy during Primary or Chronic Infection , 2006, Journal of Virology.
[78] J. Nielsen,et al. Association between larger thymic size and higher thymic output in human immunodeficiency virus-infected patients receiving highly active antiretroviral therapy. , 2002, The Journal of infectious diseases.
[79] A. d’Arminio Monforte,et al. Coinfection with hepatitis viruses and outcome of initial antiretroviral regimens in previously naive HIV-infected subjects. , 2002, Archives of internal medicine.
[80] Fernando Aiuti,et al. Failure to reconstitute CD4+ T-cells despite suppression of HIV replication under HAART. , 2006, AIDS reviews.
[81] Louis J. Picker,et al. Changes in thymic function with age and during the treatment of HIV infection , 1998, Nature.
[82] D. Haas,et al. Can immune markers predict subsequent discordance between immunologic and virologic responses to antiretroviral therapy? Adult AIDS Clinical Trials Group. , 2003, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[83] M. Clerici,et al. Comparative analysis of T-cell turnover and homeostatic parameters in HIV-infected patients with discordant immune-virological responses to HAART , 2006, AIDS.
[84] D. Douek. HIV disease progression: immune activation, microbes, and a leaky gut. , 2007, Topics in HIV medicine : a publication of the International AIDS Society, USA.
[85] D. Cooper,et al. The extent of HIV-1-related immunodeficiency and age predict the long-term CD4 T lymphocyte response to potent antiretroviral therapy , 2002, AIDS.
[86] Jeffrey N. Martin,et al. T cell activation is associated with lower CD4+ T cell gains in human immunodeficiency virus-infected patients with sustained viral suppression during antiretroviral therapy. , 2003, The Journal of infectious diseases.
[87] M. Juan,et al. Efficacy of low-dose subcutaneous interleukin-2 to treat advanced human immunodeficiency virus type 1 in persons with =250/microL CD4 T cells and undetectable plasma virus load. , 1999, The Journal of infectious diseases.
[88] B. Yip,et al. Discordant Immunologic and Virologic Responses to Highly Active Antiretroviral Therapy Are Associated With Increased Mortality and Poor Adherence to Therapy , 2005, Journal of acquired immune deficiency syndromes.
[89] R. Detels,et al. Immunologic effects of combined protease inhibitor and reverse transcriptase inhibitor therapy in previously treated chronic HIV‐1 infection , 1998, AIDS.
[90] É. Oksenhendler,et al. Effects of interleukin-2 therapy combined with highly active antiretroviral therapy on immune restoration in HIV-1 infection: a randomized controlled trial , 2003, AIDS.
[91] J. Brenchley,et al. Microbial translocation is a cause of systemic immune activation in chronic HIV infection , 2006, Retrovirology.
[92] M. Battegay,et al. Clinical progression, survival, and immune recovery during antiretroviral therapy in patients with HIV-1 and hepatitis C virus coinfection: the Swiss HIV Cohort Study , 2000, The Lancet.
[93] V. Calvez,et al. Interleukin-2 accelerates CD4 cell reconstitution in HIV-infected patients with severe immunosuppression despite highly active antiretroviral therapy: the ILSTIM study – ANRS 082 , 2002, AIDS.
[94] Ryung S. Kim,et al. Limited immune restoration after 3 years’ suppression of HIV-1 replication in patients with moderately advanced disease , 2002, AIDS.
[95] A. Haase,et al. Collagen deposition limits immune reconstitution in the gut. , 2008, The Journal of infectious diseases.
[96] A. Lazzarin,et al. Unexpected dramatic increase in CD4+ cell count in a patient with AIDS after enfuvirtide treatment despite persistent viremia and resistance mutations , 2008, Journal of medical virology.
[97] M. Battegay,et al. Characteristics, determinants, and clinical relevance of CD4 T cell recovery to <500 cells/microL in HIV type 1-infected individuals receiving potent antiretroviral therapy. , 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[98] I. Sereti,et al. HIV infection and the gut: scarred for life? , 2008, The Journal of infectious diseases.
[99] T. Fry,et al. What limits immune reconstitution in HIV infection? Divergent tools converge on thymic function. , 2001, AIDS.
[100] A. Aiuti,et al. Immunodysregulation of HIV disease at bone marrow level. , 2005, Autoimmunity reviews.
[101] M. Carrington,et al. Effect of chemokine receptor gene polymorphisms on the response to potent antiretroviral therapy , 2000, AIDS.
[102] John Bartlett,et al. Recommendations for Use of Antiretroviral Drugs in Pregnant HIV-1-Infected Women for Maternal Health and Interventions to Reduce Perinatal HIV-1 Transmission in the United States , 2004 .